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1. INTRODUCTION {#mgg3547-sec-0005}
===============

Frontotemporal dementia (FTD) is a progressive neurodegenerative syndrome with the clinical manifestations of executive dysfunction, language deficits, and behavior as well as personality changes (Perry & Miller, [2013](#mgg3547-bib-0027){ref-type="ref"}). It was the second common in young‐onset dementia, accounting for 20% dementia in 45--64 age‐group (Mercy, Hodges, Dawson, Barker, & Brayne, [2008](#mgg3547-bib-0021){ref-type="ref"}). Its clinical subtypes include behavioral variant FTD (bvFTD) and two primary progressive aphasias: nonfluent aphasia and semantic dementia. Extrapyramidal symptoms and/or amyotrophic lateral sclerosis (ALS) could also be presented in FTD patients (Fujioka & Wszolek, [2011](#mgg3547-bib-0008){ref-type="ref"}).

Frontotemporal dementia is a syndrome of genetic heterogeneity. Since *MAPT* was first identified as the causative gene of FTD in 1998, an increasing number of pathogenic genes have been reported associated with FTD including *GRN*, *C9orf72*, *VCP*, *SQSTM1*, *CHMP2B, TBK1, OPTN*, *TARDBP*, *CHCHD10*, *UBQLN2,* and *DCTN1*(Pottier, Ravenscroft, Sanchez‐Contreras, & Rademakers, [2016](#mgg3547-bib-0029){ref-type="ref"}). Most of them were also the causative genes of ALS except for *GRN* (Mackenzie & Neumann, [2016](#mgg3547-bib-0020){ref-type="ref"}; Renton et al., [2011](#mgg3547-bib-0033){ref-type="ref"}; Van Mossevelde, van der Zee, Cruts, & Van Broeckhoven, [2017](#mgg3547-bib-0043){ref-type="ref"}). Besides, approximately 15% FTD patients develop clinical features of ALS (Lomen‐Hoerth, Anderson, & Miller, [2002](#mgg3547-bib-0019){ref-type="ref"}) and up to 15% ALS patients finally reach the criteria of FTD, ALS, and FTD are now considered as ALS‐FTD spectrum, other than two separate diseases.

*TBK1* (OMIM:604834) is the causative genes of FTD‐ALS recognized recently based on a large‐scale whole‐exome sequencing study and the following variant analysis (Cirulli et al., [2015](#mgg3547-bib-0005){ref-type="ref"}; Le Ber et al., [2015](#mgg3547-bib-0017){ref-type="ref"}). Up till now, more than 70 *TBK1* variants have been reported in ALS, FTD, or FTD‐ALS patients and most were Caucasian (Ahmad, Zhang, Casanova, & Sancho‐Shimizu, [2016](#mgg3547-bib-0001){ref-type="ref"}). Its encoding protein, tumor necrosis factor receptor‐associated factor NF‐kB activator‐binding kinase 1 (TBK1), was a serine/threonine protein kinase involved in multiple cellular pathways. It has functions in neuroinflammation through NF‐κB pathway and can interact with downstream proteins such as optineurin and p62, which are involved in selective autophagy degradation. In vitro functional assessments showed that mutations of *TBK1* were associated with disruption of inflammation or autophagy pathways for the impairment of optineurin binding or IFN‐β signaling inducement, respectively (Freischmidt et al., [2015](#mgg3547-bib-0007){ref-type="ref"}).

In this study, we reported a Chinese FTD patient carrying mutation of p.Ile334Thr in *TBK1*. This mutation was firstly reported by Shu et al. in a Chinese ALS patient with no symptoms of FTD (Shu et al., [2016](#mgg3547-bib-0038){ref-type="ref"}). We also performed the in vitro functional studies to investigate its potential pathogenesis.

2. METHODS {#mgg3547-sec-0006}
==========

2.1. Ethical compliance {#mgg3547-sec-0007}
-----------------------

This research was approved by the Institutional Ethics Committee of Huashan Hospital Fudan University. The study was conducted after receiving written informed consent from the patient.

2.2. Clinical materials {#mgg3547-sec-0008}
-----------------------

The patient came from central China. The clinical materials were collected. Blood biochemical analysis (serum creatine kinase, electrolytes, glucose, retinal and liver function, thyroxine, thyroid‐stimulating hormone, and sedimentation rate) and examinations including cranial magnetic resonance imaging (MRI), positron emission computed tomography (PET/CT), electromyography plus nerve conduction velocity (EMG+NCV), electroencephalogram (EEG), and neuropsychological assessments were carried out.

The diagnosis of bvFTD was made according to the Rascovsky criteria (Rascovsky et al., [2011](#mgg3547-bib-0032){ref-type="ref"}).

2.3. Genetic test {#mgg3547-sec-0009}
-----------------

Genomic DNA was extracted from peripheral blood through a standard method (Qiagen, German). A panel containing over 4,000 known virulence genes was performed by target sequencing of the exons. In brief, all exons and their corresponding flanking regions of these genes were selected as target regions. Paired‐end sequencing was performed on Illumina HiSeq X‐ten platform. All variants different from the reference sequence were further screened by allele frequency \<1% according to 1,000 Genomes Project (<http://www.internationalgenome.org/data>), Inhouse database, ESP6500 ([evs.gs.washington.edu/EVS/](http://evs.gs.washington.edu/EVS/)), and ExAC ([exac.broadinstitute.org](http://exac.broadinstitute.org)). The synonymous variants were excluded. The phenotypes of the screened genes were compared with the clinical manifestations of the patient, and the inherited modes were considered to further exclude irrelevant genes. Then, the mutations left were confirmed by Sanger sequencing. The databases including Mutation Taster and MUpro were used to predict the pathogenicity of the variants.

The GenBank version was [CM000674.1](CM000674.1). The NCBI Reference Sequence of *TBK1* gene in this study was [NC_000012.11](NC_000012.11), with a transcript ID of ENST00000331710.5. The NCBI Reference Sequence of *TBK1* mRNA was [NM_013254.4](NM_013254.4), which encodes a protein of 729 amino acids ([NP_037386.1](NP_037386.1)). Interpretation of the variants was based on the American College of Medical Genetics and Genomics (ACMG) recommended standards (Richards et al., [2015](#mgg3547-bib-0034){ref-type="ref"}).

2.4. In vitro functional studies {#mgg3547-sec-0010}
--------------------------------

### 2.4.1. Cell culture and transfection {#mgg3547-sec-0011}

Fibroblasts were obtained from this patient and healthy controls. Cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 20% FBS (Gibco, Carlsbad, CA, USA), nonessential amino acids (Gibco), sodium bicarbonate (Sigma‐Aldrich, St. Louis, MO, USA), and 1% (vol/vol) penicillin/streptomycin/fungizone (Cellgro, Manassas, VA, USA) in an incubator at 37°C under 5% CO~2.~

HEK293T cells were cultured in DMEM with 10% FBS in an incubator at 37°C under 5% CO~2~. For transient overexpression, cells were transfected with Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) according to the manufacturer\'s instructions.

### 2.4.2. TBK1 and phosphorylated IRF3 protein analysis {#mgg3547-sec-0012}

Fibroblasts from both healthy control and the patient were washed twice with phosphate‐buffered saline (PBS) and lysed in RIPA buffer with protease and phosphatase inhibitor cocktails on ice. Proteins were resolved by SDS‐PAGE and transferred to a PVDF membrane (GE Healthcare, Little Chalfont, UK). After being blocked with 5% skim milk, the membrane was then incubated with primary antibodies overnight, followed by HRP‐conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA). Detection was made with a West‐Q Chemiluminescent Substrate Plus Kit (GenDEPOT, Barker, TX, USA).

### 2.4.3. TBK1 quantitative real‐time polymerase chain reaction (qRT‐PCR) {#mgg3547-sec-0013}

Total RNA was isolated with RNA isoplus (Takara, Japan) from the fibroblast, and cDNA was synthesized via Toyobo cDNA kit (Toyobo, Japan). Power SYBR Green PCR Master Mix and primers were used to amplifying cDNA. The relative quantities (RQs) of TATA‐binding protein (TBP) were calculated as internal control in the $2^{- \Delta\Delta C_{\text{t}}}$ method. The following primers were used in this study: *TBK1*, 5′‐CGAGATGTGGTGGGTGGAATG‐3′ and 5′‐CACAGACTGTCCATCTTCCCC‐3′; *TBP*, 5′‐CCCATGACTCCCATGACC‐3′ and 5′‐TTTACAACCAAGATTCACTGTGG‐3′.

### 2.4.4. Plasmids and constructs {#mgg3547-sec-0014}

N‐terminally GFP‐tagged wild‐type human *TBK1* cDNA was cloned into the pReceiver vector (GeneCopoeia, Rockville, MD, USA). The missense variants (c.1001T\>C, p.Ile334Thr) were introduced into wild‐type GFP‐TBK1 using the EZchange™ site‐directed mutagenesis kit (Enzynomics, Daejeon, Korea) according to the manufacturer\'s protocol. For expression in bacteria, *OPTN* cDNA fragments were amplified by PCR and subcloned into pGEX6P1 (GE Healthcare). All constructs were verified by Sanger sequencing.

### 2.4.5. GST pull‐down assay {#mgg3547-sec-0015}

Recombinant GST fusion protein GST‐OPTN was produced in *E. coli* BL‐21 cells. HEK293T cells were transfected with plasmids of wild‐type human *TBK1* and p.Ile334Thr *TBK1* separately. Both cells were lysed in lysis buffer of GST Protein Interaction Pull‐Down Kit (Thermo Scientific™, \#21516). Following experiments were performed according to the manufacturer\'s protocol.

### 2.4.6. Luciferase reporter assay {#mgg3547-sec-0016}

For luciferase reporter assays, HEK293T cells were cultured on 24‐well plates and cotransfected with a plasmid encoding an IFN‐β luciferase reporter (NanoLuc luciferase; 500 ng), pGL4.54 (firefly luciferase plasmid; 50 ng), and 1,000 ng of a plasmid‐encoding GFP‐tagged wild‐type or p.Ile334Thr *TBK1*. Transfection was performed with Lipofectamine 2000 (Invitrogen). At 24 hr post‐transfection, the cells were washed with PBS. The levels of luciferase activity (NanoLuc luciferase and firefly luciferase) were measured according to the manufacturer\'s protocol (Promega, Mannheim, Germany). Three independent experiments were performed using triplicate samples in each experiment.

### 2.4.7. Antibodies {#mgg3547-sec-0017}

Anti‐TBK1 (1:1,000; Thermo Fisher Scientific, Rockford, IL, PA5‐17478), anti‐IRF3 (1:1,000; Abcam, MA, \#ab25950), anti‐pIRF3 (Ser396) (1:500 Cell Signaling, MA, 4D4G, \#4947), anti‐OPTN(1:1,000, Proteintech, 108371‐AP), and anti‐β‐actin (1:10,000; Sigma, \#A5060) antibodies were used. The following secondary HRP‐conjugated antibodies were used for immunoblotting: goat anti‐mouse IgG (1:1,000; Santa Cruz, CA, \#sc‐2005) and goat anti‐rabbit IgG (1:1,000; Santa Cruz, \#sc‐2004).

3. RESULTS {#mgg3547-sec-0018}
==========

3.1. Clinical evaluation {#mgg3547-sec-0019}
------------------------

The patient was a 38‐year‐old female who referred to Huashan Hospital after a one‐year history of slowness in reaction, changes in personality, slow movement, and stiffness in her extremities under no predisposing cause. She has no past medical history. She had a suspicious family history as her father had "mental problem" and got lost in his thirties. During her last physical examination, two years from disease onset, the patient showed less cooperation, hyperactivity, and communication difficulties. She also showed stereotyped movement which was repeatedly rubbing her left thigh with her left hand several times and then touching her mouse or hair. Forced grasping was induced in her left hand. Her right hand presented stiffness of all fingers and could not perform fine operations. There was no muscle atrophy. Muscle strength and deep tendon reflexes were normal, while the muscle tone of her upper limbs was elevated with the right one more obvious. Bilateral Babinski signs, Hoffmann signs, and palmomental reflex were negative. The patient scored 12 in Neuropsychiatry Inventory Assessment, 39 in Dysexecutive Questionnaire, 33 in Frontal Behavioral Inventory, and 10.5 in Clinical Dementia Rating (sum of box), suggesting severe cognitive impairment particularly in executive dysfunction, attention deficit, and loss of empathy (Table [1](#mgg3547-tbl-0001){ref-type="table"}).

###### 

Neuropsychological assessments of the FTD patient carrying TBK1 variant of p.Ile334Thr

  Test                                  Score/total score                               Cutoff score   Reference
  ------------------------------------- ----------------------------------------------- -------------- ------------------------------------------------------------------------
  Mini‐mental state examination         19/30[a](#mgg3547-note-0004){ref-type="fn"}     ≥24            Strong et al. ([2009](#mgg3547-bib-0039){ref-type="ref"})
  Boston naming test                    12/30[a](#mgg3547-note-0004){ref-type="fn"}     ≥24            Jefferson et al. ([2007](#mgg3547-bib-0011){ref-type="ref"})
  Stroop test                           Fail to Conduct                                 --             Scarpina and Tagini ([2017](#mgg3547-bib-0035){ref-type="ref"})
  Auditory verbal learning test                                                                        
  AVLT‐I                                5/36[a](#mgg3547-note-0004){ref-type="fn"}      ≥12            Crossen and Wiens ([1994](#mgg3547-bib-0006){ref-type="ref"})
  AVLT‐T                                6/60[a](#mgg3547-note-0004){ref-type="fn"}      ≥23            
  Neuropsychiatry inventory             12/36                                           --             Lai ([2014](#mgg3547-bib-0015){ref-type="ref"})
  Dysexecutive questionnaire            39/80[a](#mgg3547-note-0004){ref-type="fn"}     \<10           Pedrero‐Perez et al. ([2011](#mgg3547-bib-0026){ref-type="ref"})
  Frontal behavioral inventory          33/72[a](#mgg3547-note-0004){ref-type="fn"}     \<27           Kertesz, Davidson, and Fox ([1997](#mgg3547-bib-0012){ref-type="ref"})
  Clinical dementia rating sum of box   10.5/18[a](#mgg3547-note-0004){ref-type="fn"}   \<2.5          O\'Bryant et al. ([2010](#mgg3547-bib-0024){ref-type="ref"})

FTD: frontotemporal dementia.

Score outside the normal value.

John Wiley & Sons, Ltd

Cranial MRI indicated bilateral frontotemporal atrophy (Figure [1](#mgg3547-fig-0001){ref-type="fig"}a). Her PET‐CT findings also suggested severe bilateral frontotemporal hypometabolism (Figure [1](#mgg3547-fig-0001){ref-type="fig"}b). Both EMG and EEG were normal. She was diagnosed as bvFTD and donepezil, amantadine and clonidine were prescribed.

![Imaging findings of the patient. (a) Cerebral MRI showed bilateral atrophy of frontal and temporal lobes. (b) FDG‐PET showed severe hypometabolism in frontal temporal areas](MGG3-7-na-g001){#mgg3547-fig-0001}

3.2. Mutation analysis {#mgg3547-sec-0020}
----------------------

The mean depth of target sequencing of the patient was 247.96X. The percentage of the target region with mean depth over 20X was 99.7%. According to the criteria mentioned above, only one heterozygous mutation of c.1001T\>C in *TBK1* was found, leading to a p.Ile334Thr change in exon 9 (Figure [2](#mgg3547-fig-0002){ref-type="fig"}a). The MAF of the variant TBK1 p.Ile334Thr (12:64878091 T/C) was about C = 2/102,266 in the total population. The variant was not detected in 200 Chinese seniors without medical history of neurological diseases from the community by Sanger sequencing. The evaluation by Mutation Taster (Schwarz, Cooper, Schuelke, & Seelow, [2014](#mgg3547-bib-0037){ref-type="ref"}) and MUpro (Cheng, Randall, Sweredoski, & Baldi, [2005](#mgg3547-bib-0004){ref-type="ref"}) suggested the variant be deleterious: Mutation Taster‐Disease causing, with a score of 89; MUpro‐Decrease stability, with a score of −1.85. Furthermore, according to the protein analysis on a website (<http://www.cmbi.ru.nl/hope/>), the mutant residue became smaller and less hydrophobic than the wild type, which might lead to a possible loss of interaction with other molecules on the surface of the protein (Figure [2](#mgg3547-fig-0002){ref-type="fig"}b,c). The wild‐type residue was not conserved at this position (Figure [2](#mgg3547-fig-0002){ref-type="fig"}d).

![Detection of p.Ile334Thr in *TBK1* (NP_037386.1). (a) Sanger sequencing showed the heterozygous of the mutation. (b) The overview of protein. The protein is colored gray, and the side chain of the mutant residue is colored magenta. (c) Close‐up of the mutation. The protein is colored gray, and both the wild‐type (green) and mutant (red) residue are shown. (d) Conservation among multiple species at position 334](MGG3-7-na-g002){#mgg3547-fig-0002}

3.3. Expression and function analysis {#mgg3547-sec-0021}
-------------------------------------

Compared with control fibroblasts, the mRNA level of *TBK1* in the fibroblasts with p.Ile334Thr variant was decreased by about 50% (Figure [3](#mgg3547-fig-0003){ref-type="fig"}a), and the same was found in the protein expression (Figure [3](#mgg3547-fig-0003){ref-type="fig"}b,c).

![Quantification of mRNA and protein expression level of *TBK1* in patient‐derived fibroblasts. (a) Quantitative RT‐PCR analysis of *TBK1* mRNA level in fibroblasts from healthy control and the patient with p.Ile334Thr mutation. Values are expressed as mean ± *SEM*. \*\*\**p* \< 0.0001; unpaired *t* test. (b) Western blot analysis of TBK1 and phosphorylated IRF3 protein expression level in patient‐derived fibroblasts. β‐actin was used as a loading control. (c) Quantification of TBK1 level. Values are expressed as mean ± *SEM*. \**p* \< 0.05; unpaired *t* test](MGG3-7-na-g003){#mgg3547-fig-0003}

TBK1 is known to phosphorylate IRF3 and regulate its dimerization and nucleus translocation, which participate significantly in the activation of IFN pathway in inflammation. Thus, the protein level of phosphorylated IRF3 in the fibroblasts of p.Ile334Thr variant was also evaluated and found decreased, suggesting a possible disruption of the downstream IFN pathway, which was then measured by the activation of IFN‐β promoter activity using luciferase reporter assay. Compared with the wild‐type *TBK1*, the p.Ile334Thr variant overexpressed in the HEK293T cells showed approximately 25% reduced IFN‐β signaling (Figure [4](#mgg3547-fig-0004){ref-type="fig"}a), suggesting a potential disruption of TBK1 anti‐inflammation function.

![In vitro functional analysis of *TBK1* mutation. (a) Luciferase activity in HEK293T cells cotransfected with an IFN‐β reporter plasmid and a GFP‐tagged wild‐type plasmid or a p.Ile334Thr mutation *TBK1* plasmid for 24 hr. Firefly luciferase activity served as an internal control. Values are expressed as mean ± *SEM*, \*\**p* \< 0.05. (b) Interaction between TBK1 and its downstream autophagy receptor optineurin. Lysates of a GFP‐tagged wild‐type *TBK1* or p.Ile334Thr from HEK293T cells were incubated with GST‐OPTN. Both cell lysates and bound proteins were detected by western blotting](MGG3-7-na-g004){#mgg3547-fig-0004}

CCD2 domain of TBK1 phosphorylated its downstream binding protein optineurin. Phosphorylated optineurin then took part in the autophagy. It would be of interest to further test whether autophagy defects are observed in p.Ile334Thr mutant. Here, we examined the direct interactions between TBK1 and optineurin through GST pull‐down assay. We transfected HEK293T cells with GFP‐tagged wild‐type or p.Ile334Thr form of *TBK1*. The whole cell lysates of HEK293T cell were subjected to GST pull‐down assay with GST‐OPTN. Immunoblotting showed that both wild‐type and p.Ile334Thr TBK1 could bind with optineurin (Figure [4](#mgg3547-fig-0004){ref-type="fig"}b), indicating normal function of TBK1 CCD2 domain.

According to ACMG guideline, the variant was classified as likely pathogenic (Richards et al., [2015](#mgg3547-bib-0034){ref-type="ref"}).

4. DISCUSSION {#mgg3547-sec-0022}
=============

In the present study, we described an early‐adult onset patient of FTD, carrying a *TBK1* mutation of p.Ile334Thr. The patient displayed severe behavior changes and cognitive impairment especially in executive functions but no evidence of ALS. Further experiments showed reduced transcription and expression level of *TBK1* as well as decreased IFN‐β signaling but normal binding ability with downstream autophagy receptor optineurin, indicating dysfunction of inflammatory pathway with this mutation.

The FTD‐ALS causative gene *TBK1* contributed to about 1.3% ALS, 3%--4% ALS‐FTD, and \<1% FTD with TDP‐43 pathology (Nguyen, Van Broeckhoven, & van der Zee, [2018](#mgg3547-bib-0023){ref-type="ref"}), of whom great clinical heterogeneity was presented. Considering the *TBK1* variants, clinical manifestations of reported mutations in FTD‐ALS spectrum were listed (Table [2](#mgg3547-tbl-0002){ref-type="table"}). Among the patients with *TBK1* mutations, over 50% patients were diagnosed as ALS, as well as 18% FTD, 14% FTD‐ALS, and 1.3% AD. The age at onset varied from 26 to 86, with a disease course ranging from \<1 year to more than 10 years, and approximately 18% patients died within 2 years. The most common initial symptoms included limb weakness, cognitive deficits, bulbar signs such as dysarthria and dysphagia. Interestingly, about half of the patients with *TBK1* mutations were identified with cognitive impairment and one‐thirds with bulbar symptoms. Intrafamilial and interfamilial heterogeneity were also seen in patients carrying the same mutants (Freischmidt et al., [2015](#mgg3547-bib-0007){ref-type="ref"}). The *TBK1* p.Ile334Thr mutation was first reported in a sporadic ALS (sALS) patient without cognitive impairment (Shu et al., [2016](#mgg3547-bib-0038){ref-type="ref"}). However, in our case, the patient displayed bvFTD, suggesting this mutation may be obligated to FTD‐ALS spectrum.

###### 

The clinical characteristic of patients harboring TBK1 mutations

  Function   Population   Mutation                                                  Diagnosis      Age at onset (y)   Disease duration   Family history   Initial symptoms            Cognitive impairment   MNp       Bulbar sign   Reference
  ---------- ------------ --------------------------------------------------------- -------------- ------------------ ------------------ ---------------- --------------------------- ---------------------- --------- ------------- ----------------------------------------------------------------------------------------------------------------------------------
  LoF        Japanese     c.1644‐1G\>A                                              ALS            58                 \>7                Y                Bulbar, lower limbs         N                      UMN+LMN   Y             Naruse et al. ([2018](#mgg3547-bib-0022){ref-type="ref"})
  LoF        Italian      c.358+5G\>A                                               ALS            62                 \>1.4              N                Spinal                      N                      LMN       NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
  NA         Italian      c.1644--5_1644‐2delAATA                                   ALS            43                 \>2.2              N                Spinal                      N                      UMN+LMN   NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
  LoF        French       IVS18‐2A\>G                                               FTD‐ALS        NA                 NA                 NA               NA                          Y                      NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  LoF        Spanish      p.Gln\*2                                                  FTD            56                 \>4.41             NA               NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         French       p.Thr4Ala                                                 FTD            NA                 NA                 NA               NA                          Y                      NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  NA         French       p.Gly26Glu                                                ALS            NA                 NA                 NA               NA                          NA                     NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  LoF        German       p.Lys29Argfs\*15                                          FTD            73                 4                  NA               NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  LoF        NA           p.Lys30 Glu76del                                          ALS            NA                 NA                 NA               NA                          NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  FMV        German       p.Arg47His[a](#mgg3547-note-0007){ref-type="fn"}          ALS            NA                 NA                 NA               NA                          NA                     NA        NA            Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            NA                 NA                 NA               NA                          NA                     NA        NA            
                                                                                    ALS            NA                 NA                 NA               Spinal                      NA                     NA        NA            
  LoF        Italian      p.Leu59Phefs\*16                                          ALS            36                 4.3                N                Spinal                      N                      NA        NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
  NA         Chinese      p.Leu62Pro                                                ALS            47                 2.2                N                Limb                        N                      NA        NA            Shu et al. ([2016](#mgg3547-bib-0038){ref-type="ref"})
  LoF        German       p.Thr77Trpfs\*4[a](#mgg3547-note-0007){ref-type="fn"}     ALS            35                 \>5                Y                Spinal                      NA                     NA        NA            Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            58                 3                  Y                NA                          NA                     NA        NA            
  LoF        Spanish      p.Thr79del                                                ALS‐FTD        56                 1.5                NA               NA                          Y                      NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  FMV        Bulgarian    p.Leu94Ser                                                ALS            44                 \>10               Y                Spinal                      NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         Chinese      p.Leu94Ser                                                ALS            NA                 3.2                NA               NA                          NA                     NA        NA            Pang et al. ([2017](#mgg3547-bib-0025){ref-type="ref"})
  LoF        Swedish      p.Val97Phefs\*2                                           ALS            62                 \<1                Y                NA                          NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  FMV        Swedish      p.Tyr105Cys                                               ALS            NA                 NA                 N                NA                          NA                     NA        NA            Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  LoF        Italian      p.Arg117\*                                                FTD            67                 7.1                Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             American     p.Arg117\*[b](#mgg3547-note-0007){ref-type="fn"}          FTD            68                 4                  N                NA                          Y                      NA        Y             Pottier et al. ([2015](#mgg3547-bib-0030){ref-type="ref"})
  FMV        Spanish      p.Gly121Asp                                               ALS            34                 \>5                NA               Spinal                      NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  LoF        German       p.Arg127\*                                                ALS            70                 NA                 NA               NA                          NA                     NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  FMV        German       p.Arg143Cys                                               FTD            45                 NA                 Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         French       p.Arg143Cys                                               ALS            NA                 NA                 NA               NA                          NA                     NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  LoF        French       p.Thr156Argfs\*6                                          FTD‐ALS        NA                 NA                 NA               NA                          Y                      NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  LoF        Belgian      p.Asp167del                                               ALS            60                 \<1                NA               NA                          NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  LoF        German       p.Tyr185\*[a](#mgg3547-note-0007){ref-type="fn"}          ALS            47                 \>6                Y                Spinal                      N                      UMN+LMN   N             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            37                 3                  Y                NA                          NA                     NA        NA            
                                                                                    ALS            41                 6                  Y                NA                          NA                     NA        NA            
                                                                                    ALS            40                 3                  Y                NA                          NA                     NA        NA            
  LoF        Italian      p.Asp118Asn                                               ALS            81                 \>2.9              N                Spinal                      Y                      LMN       NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
  FMV        German       p.Arg229Ser                                               ALS            47                 NA                 NA               NA                          NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  FMV        Portuguese   p.Gly244Val[c](#mgg3547-note-0007){ref-type="fn"}         FTD‐ALS        41                 \<2                Y                Bulbar                      Y                      NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  FMV        German       p.Ile246Thr                                               ALS            57                 \<2                NA               Bulbar                      NA                     NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         Belgian      p.Arg271Leu                                               FTD            80                 7                  Y                NA                          Y                      NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
  LoF        Belgian      p.Gly272_Thr331del                                        FTD            48                 2.4                Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         Scottish     p.Leu277Val                                               MND            26                 11.8               *N*              limb                        NA                     NA        NA            Black et al. ([2017](#mgg3547-bib-0002){ref-type="ref"})
  FMV        Italian      p.Lys291Glu                                               ALS            74                 \>2.75             *N*              Spinal                      Y                      LMN       NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
  FMV        Belgian      p.Lys291Glu                                               FTD            52                 \<9                Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Belgian      p.Lys291Glu                                               FTD            60                 4                  Y                NA                          Y                      NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
  FMV        Swedish      p.Ile305Thr                                               ALS            NA                 NA                 N                NA                          NA                     NA        NA            Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  FMV        American     p.Leu306Ile                                               FTD‐ALS        70                 2                  N                Y                           Y                      NA        NA            Pottier et al. ([2015](#mgg3547-bib-0030){ref-type="ref"})
  FMV        Swedish      p.Arg308Gln                                               ALS            37.9               3.5                N                Spinal                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  NA         French       p.Thr320Ile                                               ALS            NA                 NA                 NA               NA                          NA                     NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  LoF        Swedish      p.Thr320Glnfs\*40[a](#mgg3547-note-0007){ref-type="fn"}   ALS            60.1               1.9                Y                Spinal                      NA                     UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            NA                 NA                 Y                NA                          NA                     NA        NA            
  NA         Belgian      p.His322Tyr                                               ALS            64                 2                  N                NA                          NA                     NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
  NA         Chinese      p.Ile334Thr                                               ALS            51                 4                  N                Limb                        N                      NA        NA            Shu et al. ([2016](#mgg3547-bib-0038){ref-type="ref"})
  NA         Chinese      p.His336Arg                                               ALS            NA                 3.5                NA               NA                          NA                     NA        NA            Pang et al. ([2017](#mgg3547-bib-0025){ref-type="ref"})
  FMV        Italian      p.Arg357Gln                                               ALS            36                 \>1.7              N                Spinal                      N                      NA        NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
             Swedish      p.Arg357Gln                                               ALS            61.1               3                  Y                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  NA         Sardinian    p.Arg384Thr                                               ALS            NA                 1.6                Y                Limb                        N                      UMN+LMN   Y             Borghero et al. ([2016](#mgg3547-bib-0003){ref-type="ref"})
  NA         Italian      p.Ile397Thr                                               ALS            65                 \>5                N                Spinal                      Y                      UMN+LMN   NA            Pozzi et al. ([2017](#mgg3547-bib-0031){ref-type="ref"})
  LoF        Belgian      p.Ser398Profs\*11                                         ALS            59                 \>6.25             Y                NA                          NA                     NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         Chinese      p.Leu399fs[a](#mgg3547-note-0007){ref-type="fn"}          ALS            60                 5.7                Y                Right arm                   Y                      LMN       *N*           Williams et al. ([2015](#mgg3547-bib-0045){ref-type="ref"})
                                                                                    ALS            73                 8                  Y                Right leg                   NA                     UMN       NA            
  NA         American     p.Lys401Glu                                               AD             80                 10                 NA               Y                           Y                      NA        NA            Pottier et al. ([2015](#mgg3547-bib-0030){ref-type="ref"})
  LoF        Swedish      p.Ala417\*                                                FTD            68                 2.25               Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Swedish      p.Ala417\*[a](#mgg3547-note-0007){ref-type="fn"}          ALS            65                 \>7.3              Y                Spinal                      Y                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    FTD            NA                 NA                 Y                Spinal                      Y                      NA        Y             
                                                                                    ALS            56                 2                  Y                Spinal                      N                      UMN+LMN   Y             
             Swedish      p.Ala417\*                                                ALS            62.2               1.7                N                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
             Swedish      p.Ala417\*                                                FTD‐ALS        61.9               6.3                N                Spinal                      Y                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
             Swedish      p.Ala417\*                                                ALS            64.7               2.7                N                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  FMV        Portuguese   p.Ile418Val                                               FTD            53                 \<1                Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         Italian      p.Tyr424Asp                                               ALS            68                 \>0.75             NA               Spinal                      Y                      UMN+LMN   Y             Piaceri et al. ([2018](#mgg3547-bib-0028){ref-type="ref"})
  LoF        French       p.Arg440X                                                 ALS            NA                 NA                 Y                NA                          NA                     NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
             French       p.Arg440X[a](#mgg3547-note-0007){ref-type="fn"}           ALS            47                 13.0               Y                Spinal                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    FTD‐ALS        58                 3.0                Y                Spinal                      Y                      UMN       NA            
                                                                                    ALS            73                 4.0                Y                Spinal                      NA                     UMN       Y             
                                                                                    ALS                                                  Y                NA                          NA                     NA        NA            
                                                                                    FTD            60                 16.0               Y                NA                          Y                      NA        NA            
  NA         Sardinian    p.Arg444Gln                                               FTD‐ALS        72                 \>0.8              N                Cognition impairment        Y                      UMN+LMN   Y             Borghero et al. ([2016](#mgg3547-bib-0003){ref-type="ref"})
  LoF        Chinese      p.Arg444X                                                 FTD‐ALS        55                 4                  N                Cognition impairment+Limb   Y                      NA        Y             Tsai et al. ([2016](#mgg3547-bib-0041){ref-type="ref"})
  LoF        Spanish      p.Trp445\*                                                FTD+CBS        78                 \>6                NA               NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  LoF        Danish       p.Ile450Lysfs\*15[a](#mgg3547-note-0007){ref-type="fn"}   ALS            56.9               1.9                Y                Spinal                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS+D          71                 3                  Y                Spina                       Y                      NA        Y             
                                                                                    ALS            77                 \>0.7              Y                Bulbar                      N                      UMN+LMN   Y             
                                                                                    ALS            71                 2                  Y                Spinal                      N                      NA        Y             
                                                                                    ALS            51                 2.2                Y                Spinal                      N                      UMN+LMN   *N*           
             Swedish      p.Ile450Lysfs\*15[a](#mgg3547-note-0007){ref-type="fn"}   ALS            54.9               \>3.2              Y                Spinal                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            54                 3                  Y                Spinal                      N                      UMN+LMN   Y             
  LoF        German       p.Thr462Lysfs\*3                                          ALS+D          74                 0.9                Y                NA                          Y                      LMN       NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         German       p.Thr462Lysfs^†^                                          FTD‐ALS        75                 \<1                Y                NA                          Y                      NA        Y             Schonecker et al. ([2016](#mgg3547-bib-0036){ref-type="ref"})
                                                                                    FTD‐ALS        77                 \<1                Y                NA                          Y                      NA        Y             
  LoF        Korean       p.Ile472Serfs\*8                                          ALS            53                 \>3.8              N                Bulbar                      N                      UMN       Y             Kim et al. ([2017](#mgg3547-bib-0013){ref-type="ref"})
  LoF        Scottish     p.Glu476fs[c](#mgg3547-note-0007){ref-type="fn"}          MND            44                 2.83               Y                Limb                        NA                     NA        NA            Black et al. ([2017](#mgg3547-bib-0002){ref-type="ref"})
  LoF        Swedish      p.Val479Glufs\*4[a](#mgg3547-note-0007){ref-type="fn"}    FTD‐ALS        64.7               1.2                Y                Spinal                      Y                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    FTD‐ALS        58                 3.0                Y                Spinal                      Y                      NA        NA            
  LoF        French       p.Tyr482X                                                 FTD‐ALS        NA                 NA                 NA               NA                          Y                      NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  NA         Belgian      p.Ile515Thr                                               ALS            59                 \>10               NA               NA                          NA                     NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
  LoF        Belgian      p.Ser518Leufs\*32                                         ALS            64                 0.5                Y                NA                          NA                     NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
  NA         Belgian      p.Ala535Thr                                               FTD            52                 10                 Y                NA                          Y                      NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
  FMV        Portuguese   p.Met559Arg                                               ALS            60                 6                  Y                Spinal                      N                      UMN+LMN   NA            Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  FMV        Swedish      p.Ala571Val                                               ALS            66.6               1.9                N                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  NA         Spanish      p.Arg573Gly[a](#mgg3547-note-0007){ref-type="fn"}         FTD            65                 13                 NA               NA                          NA                     NA        NA            Gomez‐Tortosa et al. ([2017](#mgg3547-bib-0010){ref-type="ref"})
                                                                                    FTD            61                 6                  Y                NA                          NA                     NA        NA            
                                                                                    Dysarthria     60                 17                 Y                Memory deficit              Y                      N         Y             
                                                                                    D              65                 4                  Y                Memory deficit              Y                      N         Y             
                                                                                    PLS            66                 9                  Y                Bulbar                      NA                     UMN       Y             
                                                                                    PLS            61                 6                  Y                Bulbar                      NA                     N         Y             
  FMV        Swedish      p.Met598Val                                               ALS            61.8               \>2.5              N                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
  LoF        Belgian      p.Glu643del[a](#mgg3547-note-0007){ref-type="fn"}         FTD‐ALS        62                 11.3               Y                NA                          Y                      NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"}) and van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
                                                                                    D              71                 10                 Y                NA                          Y                      NA        NA            
                                                                                    D              86                 4                  Y                Spinal                      Y                      NA        NA            
                                                                                    ALS            69                 3                  Y                NA                          NA                     NA        NA            
                                                                                    FTD            69                 6                  Y                NA                          Y                      NA        NA            
                                                                                    D              70                 3                  Y                NA                          Y                      NA        NA            
                                                                                    FTD            63                 \>3                Y                NA                          Y                      NA        NA            
                                                                                    FTD            66                 6                  Y                NA                          Y                      NA        NA            
                                                                                    FTD            61                 13                 Y                NA                          Y                      NA        NA            
                                                                                    D              63                 6                  Y                NA                          Y                      NA        NA            
                                                                                    D              73                 11                 NA               NA                          Y                      NA        NA            
                                                                                    D              82                 4                  NA               NA                          Y                      NA        NA            
                                                                                    ALS            63                 1                  NA               NA                          NA                     NA        NA            
             German       p.Glu643del                                               ALS            NA                 NA                 N                NA                          NA                     NA        NA            Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
             German       p.Glu643del                                               ALS            NA                 NA                 N                Spinal                      NA                     UMN       Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
             Belgian      p.Glu643del                                               FTD            64                 \>9.1              Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Belgian      p.Glu643del                                               ALS            51                 1.7                Y                NA                          NA                     NA        Y             van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Belgian      p.Glu643del                                               ALS            63                 3                  NA               NA                          NA                     NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Belgian      p.Glu643del                                               FTD            70                 3.5                Y                NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Belgian      p.Glu643del                                               FTD            69                 \>8.3              NA               NA                          Y                      NA        NA            van der Zee et al. ([2017](#mgg3547-bib-0042){ref-type="ref"})
             Belgian      p.Glu643del                                               FTD            70                 \> 6               N                NA                          Y                      NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
             Belgian      p.Glu643del                                               FTD            69                 \> 7               N                NA                          Y                      NA        NA            Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
             Belgian      p.Glu643del                                               ALS            41                 \<1                N                Bulbar                      NA                     NA        Y             Gijselinck et al. ([2015](#mgg3547-bib-0009){ref-type="ref"})
  LoF        French       p.Gln655X                                                 FTD‐ALS        NA                 NA                 NA               NA                          Y                      NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  NA         French       p.Met662Thr                                               FTD‐ALS        NA                 NA                 NA               NA                          Y                      NA        NA            Le Ber et al. ([2015](#mgg3547-bib-0017){ref-type="ref"})
  NA         Sardinian    p.Met690fs[d](#mgg3547-note-0007){ref-type="fn"}          ALS            66                 \>8.6              N                Limb                        N                      LMN       Y             Borghero et al. ([2016](#mgg3547-bib-0003){ref-type="ref"})
  LoF        Danish       p.690‐713del[a](#mgg3547-note-0007){ref-type="fn"}        ALS            62.7               3.8                Y                Spinal                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            52                 2.0                Y                Spinal                      Y                      NA        Y             
                                                                                    ALS‐FTD        74                 1.2                Y                Spinal                      Y                      UMN+LMN   Y             
                                                                                    mono paresis   52                 \>0.5              Y                Spinal                      N                      LMN       N             
                                                                                    possible FTD   NA                 NA                 Y                Spinal                      Y                      NA        NA            
             Swedish      p.690‐713del[a](#mgg3547-note-0007){ref-type="fn"}        ALS            64                 2.2                Y                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    FTD‐ALS        65                 5.0                Y                Spinal                      Y                      UMN+LMN   Y             
                                                                                    possible FTD   78                 3.0                Y                NA                          Y                      NA        NA            
                                                                                    D              65                 2.0                Y                NA                          Y                      NA        NA            
  FMV        American     p.Glu696Lys                                               AD             78                 6.0                NA               NA                          Y                      NA        Y             Pottier et al. ([2015](#mgg3547-bib-0030){ref-type="ref"})
             Swedish      p.Glu696Lys                                               ALS‐FTD        61                 1.3                N                Bulbar                      Y                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
             Swedish      p.Glu696Lys[a](#mgg3547-note-0007){ref-type="fn"}         ALS            65.5               1.7                Y                Bulbar                      N                      UMN+LMN   Y             Freischmidt et al. ([2015](#mgg3547-bib-0007){ref-type="ref"})
                                                                                    ALS            NA                                    Y                Bulbar                      NA                     NA        Y             
  LoF        Scottish     p.Ala705fs[e](#mgg3547-note-0007){ref-type="fn"}          MND            46                 1.91               N                Bulbar                      NA                     NA        Y             Black et al. ([2017](#mgg3547-bib-0002){ref-type="ref"})

NCBI Reference Sequence of TBK1 protein: NP_037386.1.

AD: Alzheimer\'s disease; ALS: amyotrophic lateral sclerosis; CBS: corticobasal syndrome; D:dementia; FMV: functional missense variant; FTD: frontotemporal dementia; LoF: loss of function; MND: motor neuron disease; *N*: no; NA: not assessed; PLS: primary lateral sclerosis; Y: yes.

^a^Members of a family carrying the same TBK1 variant. ^b^Co‐exist with OPTN mutation p.Gly538Glufs\*27. ^c^Co‐exist with C9orf72 repeat expansion. ^d^Co‐exist with SQSTM1 mutation p.Arg33Val. ^e^Co‐exist with OPTN mutation p.Gln314Leu.
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Although the Caucasian accounts for most of *TBK1* mutants, mutations in *TBK1* also accounted for sALS patients of Asian population. The frequency of pathogenic or potentially toxic variants of *TBK1* in Korean and Japanese sALS patients was estimated to be 0.8% and 1.26% separately (Kim et al., [2017](#mgg3547-bib-0013){ref-type="ref"}; Tohnai et al., [2018](#mgg3547-bib-0040){ref-type="ref"}). Besides, five missense variants of *TBK1* have been reported in ALS patients of Chinese population so far, among which only the patient with p.Arg444X displayed FTD‐ALS, while the others reported no cognitive dysfunction (Tsai et al., [2016](#mgg3547-bib-0041){ref-type="ref"}). In addition, one frameshift mutation (p.Leu339fs) of Chinese origin was also found in an Australian cohort study of ALS (Williams et al., [2015](#mgg3547-bib-0045){ref-type="ref"}). Taken together, although infrequent, *TBK1* mutants can still be considered responsible for ALS‐FTD spectrum in Chinese patients.

*TBK1* encodes a multimeric kinase regulating multiple cellular pathways, especially inflammation and autophagy. It consists of 4 domains: a kinase domain (KD), an ubiquitin‐like domain (ULD), a helical scaffold dimerization domain (SDD), and a C‐terminal domain (Larabi et al., [2013](#mgg3547-bib-0016){ref-type="ref"}). *TBK1* phosphorylates transcription factor IRF3 in the C‐terminal regulatory domain, leading to its dimeration. Phosphorylated IRF3 then translocates to the nucleus, initiating the transcription of type I interferon genes. The ULD is a regulatory component of *TBK1* which controls homodimerization, kinase activation, and interactions with other molecules in the IFN pathway (Li et al., [2012](#mgg3547-bib-0018){ref-type="ref"}). The p.Ile334Thr mutation locates in the ULD region. Via in vitro functional study, we found reduced expression level of *TBK1* mRNA and protein, as well as disruption in the luciferase activity of IFN‐β, the same as p.Arg357Gln variant which is also located in the ULD region (Freischmidt et al., [2015](#mgg3547-bib-0007){ref-type="ref"}). Our results implied that *TBK1* p.Ile334Thr mutation disturbed TBK1 homodimerization and kinase activation, resulting in impairment of downstream neuroinflammatory pathways.

CCD2 mutations abrogated optineurin binding, which is necessary for selective autophagy, but not phosphorylation and activation of IRF3. TBK1 interacts with autophagy receptor proteins which can bind with ubiquitinated cargos and transport them into autophagosomes. In addition, TBK1 also participates in the process of transferring autophagosomes into hydrolytic autophagolysosome, leading to the final degradation of autophagy receptors and their target cargo (Freischmidt et al., [2015](#mgg3547-bib-0007){ref-type="ref"}). In our work, p.Ile334Thr *TBK1* seemed to have normal function in selective autophagy as its maintenance of the binding ability with optineurin through GST pull‐down assay. However, further analysis such as autophagy flux assays should be performed so as to unequivocally identify the full function of *TBK1* p.Ile334Thr in autophagy.

Although aberrant autophagy is considered as a main cause of patients with *TBK1* variants predisposed to FTD‐ALS spectrum, evidence of neuroinflammation in *TBK1* mutations also displayed its significance. Impaired migration of T cells was observed in *TBK1* knockout mice, suggesting a decreased T‐cell regulation which led to less stabilization of glial cell and proinflammatory cytokines (Komine & Yamanaka, [2015](#mgg3547-bib-0014){ref-type="ref"}). On the other hand, multiform effects of type I IFNs and cytokines have been demonstrated in neuron survival, suggesting IFN impairment in *TBK1* mutations may also lead to the pathogenesis of FTD‐ALS spectrum. In addition, possible relationship between IFN pathways and autophagy in disease has been considered (Watson et al., [2015](#mgg3547-bib-0044){ref-type="ref"}), implying that optineurin--TBK1 complexes may regulate IRF3--IFN responses. Whether such IFN impairment might also contribute to FTD pathogenesis is a possibility that remains unexplored.

There exist some limitations in this study. First, limited by the number of patients, we only detected one patient with p.Ile334Thr of TBK1. Although we detect that the mutation is likely pathogenic and can partially disturb neuroinflammatory pathway without interfering with the autophagy function of TBK1, additional patients with this mutation need to be identified with functional work. On the other hand, the decreased level of IFN‐β signaling of this mutation indicated that besides the disturbance of neuroinflammatory pathway, there may still be some unknown pathogenic mechanism under this mutation that we have not yet discovered.

5. CONCLUSION {#mgg3547-sec-0023}
=============

In this article, we reported a *TBK1* mutation of p.Ile334Thr in a Chinese bvFTD patient and classified it as likely pathogenic. Clinical evaluation confirmed the diagnosis of bvFTD, and functional analysis of the mutation demonstrated partially dysfunction of protein expression and activity of *TBK1*. Whether dysfunction of neuroinflammatory pathways reveals a general feature of p.Ile334Thr mutation of *TBK1* remains to be explored. Further study will focus on the pathogenesis of this mutation on FTD and its relationship with ALS.
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